A 2026 Molecular Psychiatry study found that oral FP802 disrupted the NMDAR/TRPM4 death complex and preserved memory-task performance in 5xFAD Alzheimer’s mice treated for 3 months.1 The finding is mechanistically sharper than a generic anti-amyloid claim: FP802 targeted a glutamate-toxicity complex downstream of amyloid stress. Research Highlights Complex formation was blocked: 5xFAD mice had increased …
A preprint in 84 older adults with epilepsy found that abnormal Alzheimer's-related blood biomarkers were common, but the biomarker categories did not line up neatly with cognitive impairment. Research Highlights Only 32.1% had normal biomarkers: 27 of 84 older adults with epilepsy were A−T−N− using blood-based amyloid, tau, and neurodegeneration markers.1 AD-continuum profiles were common: …
A 2026 review argues that neurovascular-unit dysfunction may precede amyloid-beta generation in Alzheimer’s disease and then synergize with amyloid deposition, tau pathology, inflammation, and neuronal loss.1 The model is vascular biology plus amyloid biology: blood vessels, barrier integrity, and amyloid deposition can amplify each other early enough to affect dementia risk and progression. Research Highlights …
A 2026 medicinal-chemistry study found that thymol carbamate TC-6 inhibited human butyrylcholinesterase at 3.6 nM, showed more than 2,500-fold selectivity over human acetylcholinesterase, crossed a blood-brain-barrier screening assay, and improved spatial-memory behavior in amyloid-β-injected mice. Research Highlights TC-6 hit BuChE hard: Wu et al. reported human butyrylcholinesterase (BuChE) inhibition at 3.6 nM, compared with 9,320 …
A 2026 mechanistic Alzheimer’s study found that suppressing NDST3 shifted lysosomal pH in APP695Swe neuronal cells from 5.6 back below 5.0, then reduced amyloid-β, MAPT/tau pathology, neuronal injury, and memory deficits in 3xTg-AD mice.1 Research Highlights Lysosome pH moved back down: APP695Swe-overexpressing HT22 cells had lysosomal pH around 5.6, while NDST3 knockdown re-acidified lysosomes to …
A 2026 single-cell and spatial-transcriptomics study of 21,156 brain immune cells found that late amyloid disease shifted interferon-driven neuroinflammation from microglia toward plaque-associated CD8 T cells, with T-cell frequency strongly tracking total amyloid deposits (Spearman rho = 0.844, p < 0.0001).1 The result does not turn Alzheimer’s disease into an autoimmune disease, but it makes …
A 2026 iScience study found that 45 days of clomipramine improved spatial, working, and reference memory in female APP/PS1 Alzheimer’s-model mice, apparently by blocking the E3 ubiquitin ligase Itch rather than by clearing amyloid plaques.1 Research Highlights 45-day clomipramine signal: 6-month female APP/PS1 mice received 25 mg/kg clomipramine every other day for 45 days, then …